Cathie Wood’s Ark Invest increased bets on biotechnology and AI, purchasing significant shares of Meta Platforms, Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics. The firm also added positions in Archer Aviation and Robinhood Markets. Conversely, Ark reduced exposure to Alphabet, Advanced Micro Devices, Palantir Technologies, and several healthcare stocks including Twist Bioscience and Tempus AI.